Abstract
The activation by the carcinogenic polycyclic aromatic hydrocarbon (PAH) benzo[a]pyrene (BP) of transcription factors NF-κB and AP-1 in hepatoma 27 and HepG2 cell cultures was studied. In contrast to the hepatoma HepG2 cells, cytochrome P450 isoforms and Ah-receptor are not expressed in the hepatoma 27 cells. The transcription factor NF-κB was activated only in the hepatoma 27 cells by BP treatment but not by its noncarcinogenic isomer benzo[e]pyrene (BeP). Conversely to NF-κB activation the transcription factor AP-1 was activated in the hepatoma HepG2 cells by cell treatment with BP but not in the hepatoma 27 cells. It is concluded that the NF-κB activation is caused by nonmetabolized BP molecule and not related to activation of the Ah-receptor. The transcription factor AP-1 seems to be activated as a result of the interaction of BP with the Ah-receptor. The realization of tumor promotion stage by carcinogenic PAHs treatment in dependence on the cytochrome P450 and Ah-receptor levels in the initiated cells is discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BP:
-
benzo[a]pyrene
- BeP:
-
benzo[e]pyrene
- CYP:
-
cytochromes of the P450 family
- PAH:
-
polycyclic aromatic hydrocarbon
- TCDD:
-
2,3,7,8-tetrachlorodibenzo-p-dioxin
References
Denison, M., and Whitlock, J. (1995) Biol. Chem., 270, 18175–18178.
Bock, K., and Kohle, C. (2005) Biochem. Pharmacol., 69, 1403–1408.
Ge, N., and Elferink, C. (1998) J. Biol. Chem., 273, 22708–22713.
Kim, D. W., Gazourian, L., Quadri, S. A., Romieu-Mourez, R., Sherr, D. H., and Sonenshein, G. E. (2000) Oncogene, 19, 5498–5506.
Tian, Y., Rabson, A., and Gallo, M. (2002) Chem. Biol. Interact., 141, 97–115.
Kobliakov, V. A. (1998) Biochemistry (Moscow), 63, 885–898.
Rakitsky, V., Koblyakov, V., and Turusov, V. (2000) Teratog. Carcinog. Mutagen., 20, 229–240.
Gujaeva, E. L., Ostashkina, N. M., Kondalenko, V.F., and Koblyakov, V.A. (1999) Biochemistry (Moscow), 64, 929–932.
Sharovskaja, Yu. Yu., Vaiman, A. V., Solomatina, N. A., and Kobliakov, V. A. (2004) Biochemistry (Moscow), 69, 413–419.
Sharovskaya, Y., Kobliakova, I., Solomatina, N., and Kobliakov, V. (2006) Eur. J. Cell Biol., 85, 387–397.
Beg, A. A., and Baltimore, D. (1996) Science, 274, 782–784.
Chen, F., Castranova, V., and Shi, X. (2001) Am. J. Pathol., 159, 387–397.
Wang, C. X., Mayo, M. W., and Baldwin, A. S., Jr. (1996) Science, 274, 784–787.
Karin, M., Cao, Y., Greten, F. R., and Li, Z. W. (2002) Nat. Rev. Cancer, 2, 301–310.
Hayden, M., and Ghosh, S. (2004) Genes Dev., 18, 2195–2224.
Hess, J., Angel, P., and Schorpp-Kistner, M. (2004) J. Cell Sci., 117, 5965–5973.
Li, J., Chen, H., Ke, Q., Feng, Z., Tang, M. S., Liu, B., Amin, S., Costa, M., and Huang, C. (2004) Mol. Carcinog., 40, 104–115.
Shvemberger, I. N. (1970) Tsitologiya, 12, 1057–1059.
Lyakh, L. A., Koski, G. K., Telford, W., Gress, R. E., Cohen, P. A., and Rice, N. R. (2000) J. Immunol., 165, 3647–3655.
Gasparian, A. V., Yao, Y., Kowalczyk, D., Lyakh, L. A., Karseladze, A., Slaga, T., and Budunova, I. V. (2002) J. Cell Sci., 115, 141–151.
Green, D. (2000) Cell, 102, 1–4.
Ashida, H., Nagy, S., and Matsumura, F. (2000) Biochem. Pharmacol., 59, 741–751.
Parrish, A., Fisher, R., Brghardt, R., Gndolfi, A., Brendel, K., and Ramos, K. (1998) Toxicol. Appl. Pharmacol., 152, 302–308.
Yan, Z., Subbaramaiah, K., Camilli, T., Zhang, F., Tanabe, T., McCaffrey, T. A., Dannenberg, A. J., and Weksler, B. B. (2000) J. Biol. Chem., 275, 4949–4955.
Ma, C., Wang, J., and Luo, J. (2004) Biochem. Pharmacol., 67, 1975–1983.
Pei, X., Nakanishi, Y., Takayama, K., Bai, F., and Hara, N. (1999) J. Biol. Chem., 274, 35240–35246.
Oikawa, K., Ohbayashi, T., Mimura, J., Iwata, R., Kameta, A., Evine, K., Iwaya, K., Fujii-Kuriyama, Y., Kuroda, M., and Mukai, K. (2001) Cancer Res., 61, 5707–5709.
Hossain, A., Tsuchiva, S., Minegishi, M., Osada, M., Ikava, S., Tezuka, F., Kaji, M., Konno, T., Watanabe, M., and Kikuchi, H. (1998) J. Biol. Chem., 273, 19853–19858.
Hoffer, A., Chang, C., and Puga, A. (1996) Toxicol. Appl. Pharmacol., 141, 238–247.
Solhaug, A., Refsnes, M., LaEg, M., Schwarze, P. E., Husuy, T., and Holme, J. (2004) Carcinogenesis, 25, 809–819.
Tan, Z., Chang, X., Puga, A., and Xia, Y. (2002) Biochem. Pharmacol., 64, 771–780.
Lecureur, V., Ferrec, E. L., N’diaye, M., Vee, M. L., Gardyn, C., Gilot, D., and Fardel, O. (2005) FEBS Lett., 579, 1904–1910.
Ide, F., Suka, N., Kitada, M., Sakashita, H., Kusama, K., and Ishikawa, T. (2004) Cancer Lett., 214, 35–41.
Merchant, M., Wang, X., Kamps, C., Rosengren, R., Morrison, V., and Safe, S. (1992) Arch. Biochem. Biophys., 292, 250–257.
Kobliakov, V. A. (1995) Biochemistry (Moscow), 60, 1335–1346.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © N. A. Bolotina, A. V. Gasporian, T. K. Dubavaja, V. A. Evteev, V. A. Kobliakov, 2007, published in Biokhimiya, 2007, Vol. 72, No. 5, pp. 682–689.
These authors equally contributed in this work.
Rights and permissions
About this article
Cite this article
Bolotina, N.A., Gasparian, A.V., Dubovaja, T.K. et al. Benzo[a]pyrene-dependent activation of transcription factors NF-κB and AP-1 related to tumor promotion in hepatoma cell cultures. Biochemistry Moscow 72, 552–557 (2007). https://doi.org/10.1134/S0006297907050124
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1134/S0006297907050124